Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Categories (click each to see list of all clinical trials associated with that category): FPBCC CTO Studies, Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Not open
Phase: N/A
Principal Investigator: Wildes, Tanya
Contact Information:
Melissa Eagen
meagen@unmc.edu
Summary
N/A - EAP